<DOC>
	<DOCNO>NCT00251017</DOCNO>
	<brief_summary>Transporters kidney critical detoxification elimination xenobiotics systemic circulation , thus major determinant drug response sensitivity . Transporters renal epithelium control exposure renal cell nephrotoxic drug environmental toxin thus determine xenobiotic-induced nephrotoxicity . Organic anion transporter ( OATs ) organic cation transporter ( OCTs ) two major class secretory transporter mammalian kidney . Among uptake transporter , OAT1 , OAT3 , OCT2 appear particularly important renal basolateral membrane transport large variety endogenous therapeutic compound . Recently , rapid advance single nucleotide polymorphism ( SNPs ) map apply characterize individual patient suffer adverse effect drug , drug show efficacy . The aim study identify functionally characterize OCT2 variant first step towards understand whether genetic variation OCT2 may contribute interindividual difference renal elimination vancomycin . Taiwanese patient screen 12 cod region variant OCT2 identify . The non-synonymous variant OAT1 , OAT3 , OCT2 construct characterize use vitro human renal cell model . It establish whether genetic variant OAT1 , OAT3 , OCT2 likely significant contributor intersubject variability drug response . In addition , approach toward prevention drug-induced nephrotoxicity discuss , base molecular mechanism renal accumulation drug . Perhaps researcher ' understand OAT1 , OAT3 , OCT2 pharmacogenomics may contribute goal individualized drug therapy . Development new strategy base understanding cellular handing may achieve safer effective therapy personalize medicine .</brief_summary>
	<brief_title>Impact Polymorphisms OAT1 , OAT3 , OCT2 Transportation Potential Nephrotoxic Drugs</brief_title>
	<detailed_description>Beta-lactam antibiotic , aminoglycosides , amphotericin B , cyclosporine , nonsteroidal anti-inflammatory drug , antineoplastic , antivirus drug use extensively clinical setting bear risk nephrotoxicity . This side effect dose-dependent attribute mainly accumulation drug renal proximal tubule . When assess nephrotoxicity , dosage tubular secretion system , allow transport drug blood urine via tubular cell , important factor . This study design investigate renal transporter work renal secretion specific drug . Transporters kidney critical detoxification elimination xenobiotics systemic circulation , thus major determinant drug response sensitivity . Transporters renal epithelium control exposure renal cell nephrotoxic drug environmental toxin thus determine xenobiotic-induced nephrotoxicity . Organic anion transporter ( OATs ) organic cation transporter ( OCTs ) two major class secretory transporter mammalian kidney . Among uptake transporter , OAT1 , OAT3 , OCT2 appear particularly important renal basolateral membrane transport large variety endogenous therapeutic compound . Recently , rapid advance single nucleotide polymorphism ( SNPs ) map apply characterize individual patient suffer adverse effect drug , drug show efficacy . The aim study identify functionally characterize OCT2 variant first step towards understand whether genetic variation OCT2 may contribute interindividual difference renal elimination vancomycin . Taiwanese patient screen 12 cod region variant OCT2 identify . The non-synonymous variant OAT1 , OAT3 , OCT2 construct characterize use vitro human renal cell model . It establish whether genetic variant OAT1 , OAT3 , OCT2 likely significant contributor intersubject variability drug response . In addition , approach toward prevention drug-induced nephrotoxicity discuss , base molecular mechanism renal accumulation drug . Perhaps understanding OAT1 , OAT3 , OCT2 pharmacogenomics may contribute goal individualized drug therapy . Development new strategy base understanding cellular handing may achieve safer effective therapy personalize medicine .</detailed_description>
	<mesh_term>Vancomycin</mesh_term>
	<criteria>Subjects 16 year age old , either sex . Subjects medication include vancomycin Subjects realistic expectation benefit limitation augmentation procedure , determine willingness sign inform consent form carefully explain . Subjects medical condition increase risk study participation ( include pregnancy poor renal function ) Subjects take medication ( nephrotoxicants ) could confound study result . Subjects present history autoimmune disorder , septic shock , multiple organ failure . Subjects renal failure undergoing dialysis ( hemodialysis [ HD ] continuous ambulatory peritoneal dialysis [ CAPD ] ) , continuous venovenous hemofiltration ( CVVH ) , continuous arteriovenous hemodiafiltration ( CAVHDF ) .</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2012</verification_date>
	<keyword>single nucleotide polymorphism ( SNPs )</keyword>
	<keyword>personalize medicine</keyword>
	<keyword>Subjects 16 year age old , either sex .</keyword>
	<keyword>Subjects medication include vancomycin</keyword>
</DOC>